Bausch+Lomb Results Presentation Deck
Early Stage Launches and Near-term Pipeline Products to Watch ¹
SiHy Daily
Lumify® Expansion Opportunities
SeeLuma TM Fully Digital Surgical
Visualizatio
IC-8® Apthera T™
Product
eye TELLIGENCE® Digital Platform
MIEBO ™M 2
en Vista Envy TM
en Vista® Trifocal IOL
(3D Microscope)
MIMSⓇ Minimally Invasive Surgical Procedure
en Vista Aspire ™
en Vista® Extended Range Monofocal IOL
BAUSCH+ LOMB
en Vista Beyond ™
en Vista® Extended Depth of Focus IOL
Status
Launched SVS in ~50 countries, including China in
2Q23; Multifocal launched in U.S.
Eye Illuminations - Launching this year
Launching now in U.S. and Western Europe
Beta software testing ongoing. Regulatory
assessments complete
Available in select markets across Europe, as well as
in Australia, New Zealand and Singapore
Entered into exclusive European distribution
agreement with Sanoculis
FDA approval in May 2023
Filed in Canada 1Q23
Canada, EU and U.S. submissions in process
U.S. and Canada submitted 1Q23
EU submitted 2Q23
Clinical study expected to begin 4Q23
1. See Slide 1 for further information on forward-looking statements.
2. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of
Miebo TM in the United States and Canada.
Upcoming Milestone
Geo-expansion continues
Toric launch expected in 2024
Preservative Free submitted 2Q23
Allergy submission expected 2024
Additional countries expected to follow
U.S. commercial release in process
U.S. launch in process
EU launch in process
Launch expected in U.S. in 3Q23
Expect U.S., EU, Canada launch in 2024
(includes Toric versions and new EyeGility inserter)
Expect U.S. and Canada launch 2H23
(includes Toric; new Eye Gility inserter to be added in 2024)
EU launch expected in 2024 with EyeGility inserter
Expect 2025/2026 launch
22View entire presentation